Want to see CGTX full AI Analyst Report?
CGTX Stock Chart & Stats
$0.92
-$0.04(-4.24%)
At close: 4:00 PM EDT
$0.92
-$0.04(-4.24%)
Day’s Range― - ―
52-Week Range$0.55 - $3.83
Previous CloseN/A
Volume451.33K
Average Volume (3M)2.91M
Market Cap
$99.85M
Enterprise Value$70.05
Total Cash (Recent Filing)$34.01M
Total Debt (Recent Filing)$511.00K
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Nov 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding95,093,740
10 Day Avg. Volume2,171,776
30 Day Avg. Volume2,911,286
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside226.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway Clarity For Lead AssetA productive FDA meeting that yields a clear path toward a registrational Phase 3 for zervimesine materially reduces regulatory ambiguity. This durable outcome supports program prioritization, trial design confidence, and de-risks next-stage planning over the coming 6–18 months.
Near-term Cash Runway Supported By GrantsHaving ~$34.8M cash plus $21.6M in obligated grant funding, with management guidance to fund operations into Q4 2027, provides a durable runway. This reduces immediate dilution pressure and allows execution of planned Phase 2/3 activities and data readouts without urgent financing.
Conservative Balance Sheet With Low LeverageVery low leverage and positive equity give the company financial flexibility during the clinical development phase. Low debt reduces refinancing risk and preserves capacity to raise equity or access non-dilutive grants, supporting multi-quarter program execution.
Bears Say
Zero Revenue Commercial RiskAs a pre-commercial biotech with no product revenue, the company lacks internally generated funding and commercial validation. This structural reality makes future sustainability contingent on clinical success and external financing, a persistent multi-quarter risk.
Ongoing Negative Cash Flow And Burn VariabilityConsistent negative operating and free cash flow means the business consumes capital to fund trials. Although burn has improved, volatility in FCF and continued negative cash generation creates structural dependence on external financing and can pressure timelines or program scope.
Single-lead Candidate Concentration RiskCorporate value and strategy are concentrated on zervimesine; success or failure of this single late-stage program will disproportionately affect the firm's prospects. This clinical binary outcome creates material execution and valuation risk over the next 6–24 months.
Cognition Therapeutics News
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.55 and its highest was $3.83 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $99.85M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 98 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.063 by $0.023.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 95,093,740 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.063. Following the earnings report the stock price went down -4.425%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Currently, no hedge funds are holding shares in CGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cognition Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (226.09% Upside)
$3.00 (226.09% Upside)
Hedge Fund Trend
Decreased
By 151.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
291.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
98.23%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
CGTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress in clinical efficacy signals and strategic cost management, extending the cash runway. However, challenges remain with increased net losses, NASDAQ compliance issues, and uncertain funding partnerships. The sentiment is balanced by advancements in manufacturing and patent filings.View all CGTX earnings summariesCGTX Stock 12 Month Forecast
Average Price Target
$3.00
▲(226.09% Upside)
Technical Analysis
Tonix Pharma
―
Adicet Bio
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
10.17% Insiders
4.06% Mutual Funds
1.76% Other Institutional Investors
80.18% Public Companies and
Individual Investors